Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Single-Dose Of Omaveloxolone In Children ≥2 To <16 Years Of Age With Friedreich's Ataxia

Trial Profile

An Open-Label, Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Single-Dose Of Omaveloxolone In Children ≥2 To <16 Years Of Age With Friedreich's Ataxia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Biogen; Reata Pharmaceuticals

Most Recent Events

  • 21 May 2025 Given protocol has been amended as above-1) Number of treatment arms has been changed from 4 to 7. 2) Primary endpoints has been amended.3) Planned number of patients has been changed from 20 to 35.
  • 21 May 2025 Planned number of patients changed from 20 to 35.
  • 08 Jul 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top